Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

9 Pages (Click to Jump) V   1 2 3 4 > » 

seeva222
Posted on: Today, 03:07 AM


Group: Member
Posts: 1,679

You are reckoning out your pie hole. I have no idea why you would even think that was remotely true. Censoring was happening here it certainly isnt happening on the new board nor would I expect it to as I know the people who run it
  Forum: By Share Code

seeva222
Posted on: Yesterday, 10:54 PM


Group: Member
Posts: 1,679

You clearly have no reliable insiders.. Not only is fear and anxiety low, info is free flowing. Right now its all information and high-fives Im sure theyll be some challenges along the way
  Forum: By Share Code

seeva222
Posted on: Jul 6 2020, 09:14 PM


Group: Member
Posts: 1,679

What was the news?
  Forum: By Share Code

seeva222
Posted on: Jul 2 2020, 04:17 PM


Group: Member
Posts: 1,679

They have added some good instos recently... though I own more shares than many of them. So there's some movement.

They also seem to have made their path much harder than it had to be.Let's hope they up their game. They aren't a merry band of little fighters trying to fight through the system anymore, they're a billion dollar company, yet the Miami office seems to be the only one doing any volume of implants right now. LA has been a mess, Detroit isn't out of the gate, I would imagine that SLC, Charleston, Portland aren't either.
  Forum: By Share Code

seeva222
Posted on: Jul 2 2020, 11:05 AM


Group: Member
Posts: 1,679

I don't actually think they should be focused on retail investors. I would put all of my eggs into courting instos with long-term hold philosophies. Retail investors suck. Short-term investors suck.
  Forum: By Share Code

seeva222
Posted on: Jun 30 2020, 01:46 AM


Group: Member
Posts: 1,679

How about an Ops person to smooth out the process to get EPP patients Scenesse? It would pay for itself and all of these other jobs in three months.

Wait... have I suggested this before?
  Forum: By Share Code

seeva222
Posted on: Jun 29 2020, 11:10 PM


Group: Member
Posts: 1,679

Couple of thoughts:

    Generally, I'm on management's side when it comes to providing shareholder information (even thought I'm on the investor side here.) Investors are not management or the board, we don't have access to all of the intel (nor should we) and we generally make some really bad assumptions about what's going on and can cause disruption. I used to handle IR advisory for mid-sized companies for a few years. Shareholder management contention is not a new concept. For example, I'm not sure Clinuvel should or should have chased Covid indications at the expense of EPP, vitiligo etc., I just don't know enough. There are great companies run by highly ethical people who, as a matter of practice, share verrrrryyyy little with shareolders.

    That said, public information is public information and we do have voting rights. It seems that this industry, in particular, is prone to shareholder abuse. Information like EPP patients describing their interactions with Clinuvel as a "battle", incomplete submissions, absolutely absurd CEO performance packages (based upon peer performance in a recession) need to be discussed and vetted and InvestClinuvel will allow us a forum to do so.

    I hope InvestClinuvel doesn't become agent of war born of frustration against management. That can be highly counterproductive. There's some good research done here (not by me) that I actually think I/C could become a value driver. I'll have an ore in both waters. Titles like "you can't handle the truth" and "do you want a condo with that implant" "the public company that doesn't want to be" may feel rebellious, but ultimately that makes me a big wary.

    Cheers all, looking forwad to July receipt numbers.
  Forum: By Share Code

seeva222
Posted on: Jun 28 2020, 03:43 AM


Group: Member
Posts: 1,679

That they're spending any time at all on this while the struggle to meet the demand of EPP patients ( many are stuck in purgatory) and have sooo many irons in the fire points to some weird inadequacy.

Spend your time training more us clinics.
  Forum: By Share Code

seeva222
Posted on: Jun 27 2020, 11:22 AM


Group: Member
Posts: 1,679

Im Portugeseman!
  Forum: By Share Code

seeva222
Posted on: Jun 26 2020, 12:43 PM


Group: Member
Posts: 1,679

An uho special:

In a nutshell Msh/Scenesse prevents tumors and skin cancer with reliable evidence.
  Forum: By Share Code

seeva222
Posted on: Jun 26 2020, 12:25 PM


Group: Member
Posts: 1,679

I wonder if the new site will allow the EPP patients to share how hard its been to work with Clinuvel?
  Forum: By Share Code

seeva222
Posted on: Jun 25 2020, 12:12 AM


Group: Member
Posts: 1,679

2019
  Forum: By Share Code

seeva222
Posted on: Jun 24 2020, 12:35 AM


Group: Member
Posts: 1,679

Isn't Clinuvel hinting at COVID treatment WRT stroke with it's recent SC?
  Forum: By Share Code

seeva222
Posted on: Jun 23 2020, 07:40 AM


Group: Member
Posts: 1,679

Covid seems to be worse?

In the three weeks beginning mid-March, Mocco saw 32 stroke patients with large blood blockages in the brain, double the usual number for that period.

J Mocco, MD, Director of Mount Sinai's Cerebrovascular Center, David Reich, MD and President and COO of The Mount Sinai Hospital, and Hooman Poor, MD, an ICU doctor pose together outside the hospital in Manhattan, during the outbreak of the coronavirus disease (COVID-19) in New York City, New York, U.S., April 17, 2020. REUTERS/Jeenah Moon
Five were unusually young, under age 49, with no obvious risk factors for strokes, which is crazy, he said. Very, very atypical. The youngest was only 31.

https://www.reuters.com/article/us-health-c...s-idUSKCN22421Z
  Forum: By Share Code

seeva222
Posted on: Jun 23 2020, 05:39 AM


Group: Member
Posts: 1,679

What they don't tell you about surviving COVID-19.

These are my observations (of hospitalized patients):
1) Everybody is so swollen their skin has blisters and is so tight it looks like its about to burst, from head to heel. And skin so dry peeling and flaky that to slather Vaseline on every shift is almost necessary all over.
2) Everybodys skin is weeping clear fluid and has sores and the skin just slides off with slightest turn or rub, all over the body.
3) Everybodys blood is thick as slush. Cant figure out whats making it clot like that, but its dark and thick.
4) Everybodys kidneys are failing. Urine dark or red, which could contribute to the swelling, but we dont know yet.

It certainly seems like a drug with anti-inflammatory properties would be helpful

https://www.sfgate.com/news/editorspicks/ar...ng-15347792.php
  Forum: By Share Code

seeva222
Posted on: Jun 22 2020, 04:52 AM


Group: Member
Posts: 1,679

Clinuvel actuall pretty active on Linkedin

https://www.linkedin.com/posts/clinuvel-pha...6880670720-IKf-
  Forum: By Share Code

seeva222
Posted on: Jun 21 2020, 02:51 AM


Group: Member
Posts: 1,679

Interesting that they're not going after vitiligo
  Forum: By Share Code

seeva222
Posted on: Jun 19 2020, 12:25 PM


Group: Member
Posts: 1,679

It's the first time in many months that I've felt like the shorters are actually in a bad spot. The quality of intitutional ownership coupled with US sales and multiple indications tell a pretty convincing story.
  Forum: By Share Code

seeva222
Posted on: Jun 19 2020, 02:20 AM


Group: Member
Posts: 1,679

Any idea how this compares to last year?
  Forum: By Share Code

seeva222
Posted on: Jun 18 2020, 07:33 AM


Group: Member
Posts: 1,679

How many patients? Great find.
  Forum: By Share Code

seeva222
Posted on: Jun 18 2020, 02:40 AM


Group: Member
Posts: 1,679

Getting approved Scenesse: Its an absolute struggle, hope is fading for the summer
Getting MT7117 On trial: Its a Wonderful process

  Forum: By Share Code

seeva222
Posted on: Jun 17 2020, 12:10 AM


Group: Member
Posts: 1,679

Hes on fire Scenesse could be a preventative intervention on high risk patients. There are multi-millions of patients. The use would be almost all patients.
I could easily see sales here of at least $10 billion in sales of Scenesse here. Rather than over several years, overnite this could make Clinuvel a $40 Billion in Market Capital and one of the top ten pharmaceutical companys in world. Still dwarfed by Merck and Pfizer though.
  Forum: By Share Code

seeva222
Posted on: Jun 16 2020, 09:07 AM


Group: Member
Posts: 1,679

A research team at the University of Miami Miller School of Medicine has shown that a small protein called melanocyte-stimulating hormone (a-MSH) reduces the inflammation associated with sarcoidosis.

https://physician-news.umiamihealth.org/ant...dosis-patients/

Melanocortin systems are well-known for their regulation of skin pigmentation and steroidogenesis. Interest in melanocortin receptor agonists in pulmonary medicine stems from their role as potential modifiers of inflammatory disease. In this review, we provide insight into the structures and functionality of melanocortin receptors and their agonists in pulmonary inflammatory and fibrotic diseases.

https://www.frontiersin.org/articles/10.338...2019.00145/full
  Forum: By Share Code

seeva222
Posted on: Jun 16 2020, 03:03 AM


Group: Member
Posts: 1,679

Collectively these studies have exhibited a clinical application for α-MSH in maintaining vascular homeostasis. Through its favourable regulation of eNOS via post-transcriptional modifications and preventing ONOO- generation, α-MSH increases the bioavailability of NO in the endothelial cells of the vasculature. Sufficient concentrations of NO can therefore stimulate vasoprotective changes in diseases who origins result from a loss of NO production or availability.
  Forum: By Share Code

seeva222
Posted on: Jun 16 2020, 02:53 AM


Group: Member
Posts: 1,679

In case youre wondering if Clinuvel is getting any better at handling the operations around distribution Theyre not. Patients are in Purgatory waiting for Clinuvel their act together. Meanwhile every lost month is lost dollars.
  Forum: By Share Code

seeva222
Posted on: Jun 16 2020, 12:24 AM


Group: Member
Posts: 1,679

It certainly means they're exploring the possibility.
  Forum: By Share Code

seeva222
Posted on: Jun 15 2020, 02:34 AM


Group: Member
Posts: 1,679

PAD, does this work?
  Forum: By Share Code

seeva222
Posted on: Jun 13 2020, 02:31 AM


Group: Member
Posts: 1,679

Thats probably a pretty big market.
  Forum: By Share Code

seeva222
Posted on: Jun 13 2020, 12:32 AM


Group: Member
Posts: 1,679

CAn someone translate? wink.gif
  Forum: By Share Code

seeva222
Posted on: Jun 12 2020, 02:43 PM


Group: Member
Posts: 1,679

Lung damage after a cytokine storm - Graphic
  Forum: By Share Code

seeva222
Posted on: Jun 12 2020, 09:32 AM


Group: Member
Posts: 1,679

200k cases a year.


The average clinical course among these 22 patients was 10 years from the onset of the disease. The average age at death was 39 years. Patients who died of central nervous system and cardiac sarcoidosis were younger, and their clinical course was shorter.

  Forum: By Share Code

seeva222
Posted on: Jun 12 2020, 08:12 AM


Group: Member
Posts: 1,679

Good source
  Forum: By Share Code

seeva222
Posted on: Jun 12 2020, 06:19 AM


Group: Member
Posts: 1,679

Some good news: Business is booming in the Miami office.
  Forum: By Share Code

seeva222
Posted on: Jun 11 2020, 03:53 AM


Group: Member
Posts: 1,679

Mt Sinai and a Boston location should be top priorities. Perhaps Cleveland as well.


  Forum: By Share Code

seeva222
Posted on: Jun 10 2020, 01:11 AM


Group: Member
Posts: 1,679

What would it take to get a Dr Or PA certified ?
  Forum: By Share Code

seeva222
Posted on: Jun 9 2020, 01:18 PM


Group: Member
Posts: 1,679

New York is not the Entire NorthEast. Boston would be a better choice.
  Forum: By Share Code

seeva222
Posted on: Jun 9 2020, 12:46 PM


Group: Member
Posts: 1,679

How much "setup" is there? Training (which as PAD noted is really simple), insurance which can be done virtually and getting them product. Maybe I'm missing something,
  Forum: By Share Code

seeva222
Posted on: Jun 9 2020, 10:31 AM


Group: Member
Posts: 1,679

If you squint you can see that in the most populous part of the country were missing a center... the Northeast. They all have to go to Florida, which is ridiculous given that the competitor is in Boston
  Forum: By Share Code

seeva222
Posted on: Jun 9 2020, 01:03 AM


Group: Member
Posts: 1,679

I'm not sure you want to rely on the APF since they are committed to a competitor, which frankly they should be. They should be trying to get every treatment possible going forward. But, from CUV's perspective, putting such responsibility on a non-profit with competing interests is not smart.

The APF is a bunch of ass-kickers, but they're going to be kicking ass for competitors as well as CUV.

I realize it's an injection, but hasn't CUV committed to a specific training process?
  Forum: By Share Code

seeva222
Posted on: Jun 9 2020, 12:43 AM


Group: Member
Posts: 1,679

Now on a positive note the fact that the offices are jammed up means of course there is demand out there.Its okay to not anticipate this type of demand or competitors, you just need to adjust quickly and decisively.
  Forum: By Share Code

seeva222
Posted on: Jun 8 2020, 10:42 PM


Group: Member
Posts: 1,679

* Clinuvel needs to hire BOTH a full-time trainer to get other doctors ready to deliver and a full time admin to help people get approved. Or hire a consutant.

One thing is clear. People are very frustrated with the approval process for Scenesse right now. With some deciding it's easier to get into a MT 7117 trial than get Scenesse (which is absurd).

Part of the problem is that Clinuvel is relying way too much on the APF. The APF is great, but this shouldn't be their job and they have more incentive to steer patients into the MT-7117 trial.

The other problem is that between having to get approved, get scheduled and actually travel to individual locations, Clinuvel has made it too hard when other options could potentially loom. They need more locations.

EACH patient lost has a lifetime value of at least $500k. So, if you hire two people and those two people save only one patient, they will have paid for themselves 2-3x. If they save 100 patients, that's $50-million in lifetime value.

I completely get the need to conserve cash, but this is landgrab situation.

Throwing away business is never a good strategy.
  Forum: By Share Code

seeva222
Posted on: Jun 6 2020, 01:53 PM


Group: Member
Posts: 1,679

As far as I can tell, the retail price is irrelevant. Its the price you negotiate from
  Forum: By Share Code

seeva222
Posted on: Jun 3 2020, 01:58 PM


Group: Member
Posts: 1,679

That was the most idiotic trigger Imaginable. A recession was inevitable, the short attack destroyed value. All he has to do is not kill the company to get the bonus.
  Forum: By Share Code

seeva222
Posted on: Jun 3 2020, 12:34 AM


Group: Member
Posts: 1,679

800k per center per month x [How many centers can we get trained] = Good Math

Every center is a cash cow and a strategic box out.

Am I repeating myself?

Pay extra to get centers up and running now, it's free money. Take the money!!!

I know, I sound like penguin. But...

take the money.
  Forum: By Share Code

seeva222
Posted on: Jun 2 2020, 02:35 PM


Group: Member
Posts: 1,679

If each one books 5 patients a week, that's $800k a month per center.

Private Jet to Boston 47k.

Screwing MT 7117, priceleess
  Forum: By Share Code

seeva222
Posted on: Jun 2 2020, 01:57 PM


Group: Member
Posts: 1,679

Good, since LA has been dysfunctional. It would help if Dr. Grime's office could at least spell EPP correctly and return phone calls.

Now, get a center in Boston... there are a gabillion derms in the area. Fly someone out there on a private plane to train them, it will pay for itself in three doses and reduced patients for MT7117 testing

https://profiles.stanford.edu/joyce-teng
  Forum: By Share Code

seeva222
Posted on: Jun 1 2020, 10:33 PM


Group: Member
Posts: 1,679

And Vitiligo willl have a high probability of approval...
  Forum: By Share Code

seeva222
Posted on: Jun 1 2020, 09:01 AM


Group: Member
Posts: 1,679

40k Math:

100 US patients = $16-million a year
1000 US patients = $160-million a year

  Forum: By Share Code

seeva222
Posted on: May 30 2020, 11:43 AM


Group: Member
Posts: 1,679

PW and team should be moving heaven and earth to get Scenesse into the hands of patients in Columbus and Boston.
  Forum: By Share Code

seeva222
Posted on: May 25 2020, 09:40 AM


Group: Member
Posts: 1,679

no, thats right it was 41k when I called.
  Forum: By Share Code

seeva222
Posted on: May 24 2020, 03:44 PM


Group: Member
Posts: 1,679

Simone give that woman free Scenesse
  Forum: By Share Code

seeva222
Posted on: May 24 2020, 05:10 AM


Group: Member
Posts: 1,679

Hey PW, what's your competitive response here? Don't sleep on this or it will bite your bonus.
  Forum: By Share Code

seeva222
Posted on: May 23 2020, 11:57 PM


Group: Member
Posts: 1,679

Hey Clinuvel. Move heaven and earth to get centers set up in their target cities. Pull in all your contacts. And get it done.
  Forum: By Share Code

seeva222
Posted on: May 23 2020, 10:51 AM


Group: Member
Posts: 1,679

Peptide used to treat corona in Cuba
https://www.reuters.com/article/us-health-c...source=facebook
  Forum: By Share Code

seeva222
Posted on: May 21 2020, 11:06 AM


Group: Member
Posts: 1,679

I believe so. Im me.
  Forum: By Share Code

seeva222
Posted on: May 21 2020, 09:45 AM


Group: Member
Posts: 1,679

BTW, one thing I haven't seen mentioned is using Scenesse at the onset of vitiligo to halt the progression of it. I suspect it will be a first line defense at the earliest diagnosis.
  Forum: By Share Code

seeva222
Posted on: May 21 2020, 01:08 AM


Group: Member
Posts: 1,679

They seem to have deemphasized M&A... phew
  Forum: By Share Code

seeva222
Posted on: May 20 2020, 06:11 PM


Group: Member
Posts: 1,679

What is the status in Japan for EPP? I don't see that anywhere
  Forum: By Share Code

seeva222
Posted on: May 20 2020, 09:36 AM


Group: Member
Posts: 1,679

If you could show DNA repair... how big would that be? That seems like a holy grail
  Forum: By Share Code

seeva222
Posted on: May 19 2020, 10:51 PM


Group: Member
Posts: 1,679

Opening new locations = printing money
  Forum: By Share Code

seeva222
Posted on: May 19 2020, 10:16 AM


Group: Member
Posts: 1,679

“ The clinical demand for SCENESSE® surpasses our expectations so far, the news reached us that more EPP patients are flying from all parts of the US to seek treatmenT”
  Forum: By Share Code

seeva222
Posted on: May 19 2020, 12:33 AM


Group: Member
Posts: 1,679

So....

    The EPP engine now looks safely into the $100-million per year + range between Europe, US, China, Japan (totally forgot about it) and Australia. When does Japan evaluate?
    Vitiligo in the US now looks very promising and the same people reviewing the NDA were the ones who reviewed EPP.
    Cosmetic, DNA repair and now it looks like sort of anti-inflammatory indications are in the works.
    VPP is progressing.


If not for corona hell, we'd be talking tax implication.s
  Forum: By Share Code

seeva222
Posted on: May 17 2020, 08:53 AM


Group: Member
Posts: 1,679

nation therapy was
conducted.
Combination therapy (n ¼ 18) was superior to
placebo, with a statistically significant decrease in the
median Vitiligo Area Scoring Index scores for total,
head and neck, hands, upper extremities, trunk, and
lower extremities at day 140 and thereafter (P\.05)
(Table I). Statistically significant reductions in Vitiligo
European Task Force area percentage scores for total
body, head and neck, and trunk were observed at
day 196 (P \.05).
Onset of repigmentation was observed the earliest
for upper extremities (median, 10.5 days) and
trunk (median, 13 days) (Fig 1) and the latest for
hands and feet (median, 36 days for both).
Combination therapy was well tolerated. Notable
adverse events included erythema and pruritus,
which were likely related to NB-UVB. Nail
pigmentation was possibly due to afamelanotide
activating melanogenesis.
  Forum: By Share Code

seeva222
Posted on: May 14 2020, 04:02 AM


Group: Member
Posts: 1,679

Anyone else first see cyanide?
  Forum: By Share Code

seeva222
Posted on: May 12 2020, 11:06 PM


Group: Member
Posts: 1,679

What email did you send to your state senators? Seems like somehting others could do if they want to.
  Forum: By Share Code

seeva222
Posted on: May 12 2020, 11:43 AM


Group: Member
Posts: 1,679

It's just sophomoric to engage in a public battle with shareholders. It only invites ridicule.
  Forum: By Share Code

seeva222
Posted on: May 11 2020, 11:37 PM


Group: Member
Posts: 1,679

"the penetrance of the EPP phenotype in the Japanese population is expected to be higher than in the Western countries due to the high frequency of the IVS3-48C polymorphism (43%) (19)." I didn't realize Japan was a large market. 126-million people. It's listed at the same as Oz. Does anyone have info on how close we are there?
  Forum: By Share Code

seeva222
Posted on: May 10 2020, 11:46 AM


Group: Member
Posts: 1,679

They've already ruled it out. Perhaps for the reasons JT mentioned.
  Forum: By Share Code

seeva222
Posted on: May 8 2020, 12:27 PM


Group: Member
Posts: 1,679

Their logic is that they didn't believe Nasdaq would add enough liquidity to warrant the switch. (That's what I remember anyway.)
  Forum: By Share Code

seeva222
Posted on: May 7 2020, 07:04 PM


Group: Member
Posts: 1,679

It makes no sense that they were aiming for just 3 centers in 2020. It's a simple freaking procedure and paperwork.
  Forum: By Share Code

seeva222
Posted on: May 7 2020, 12:16 AM


Group: Member
Posts: 1,679

https://www.youtube.com/watch?v=6k-etrnvY4s...eature=youtu.be

<iframe width="560" height="315" src="https://www.youtube.com/embed/6k-etrnvY4s" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
  Forum: By Share Code

seeva222
Posted on: May 6 2020, 11:34 PM


Group: Member
Posts: 1,679

A recent study by the Porphyria Center in Rotterdam (The Netherlands), in which all Dutch EPP patients are treated with afamelanotide, confirms the safety and effectiveness of afamelanotide even under everyday conditions. The 117 patients from the Netherlands spent an average of 6.1 hours longer outdoors on treatment and had a significantly higher quality of life compared to before treatment. If patients developed phototoxic reactions, they were less painful during treatment.
  Forum: By Share Code

seeva222
Posted on: May 5 2020, 01:40 AM


Group: Member
Posts: 1,679

What exactly is stopping us from rolling this out to more than 3 centres in the US in 2020? The training is simple. Coverage is in place. Is it hiring a body in the US for 80k a year to get many times that over back in revenue?
  Forum: By Share Code

seeva222
Posted on: May 3 2020, 12:46 PM


Group: Member
Posts: 1,679

Someone should excerpt that Logada presentation for investclinuvel. I'll bet that got a few instos attention
  Forum: By Share Code

seeva222
Posted on: May 2 2020, 10:03 PM


Group: Member
Posts: 1,679

I thought they exited ?
  Forum: By Share Code

seeva222
Posted on: May 2 2020, 12:10 AM


Group: Member
Posts: 1,679

Vaso-activity, anti-phlogitism and DNA Repair?

Can someone give me some perspective on this? These seem like beyond blockbuster indications. I actually thinking of buying more as we face a downturn.


  Forum: By Share Code

seeva222
Posted on: May 1 2020, 11:45 PM


Group: Member
Posts: 1,679

Uh, wow. This is exactly the investor profile we want. Long-term, strategic holds. Wow.
  Forum: By Share Code

seeva222
Posted on: May 1 2020, 10:30 AM


Group: Member
Posts: 1,679

“Most pleasing was that the senior managers and decision makers within the FDA’s Division of Dermatology and
Dental Products were actively engaged in the discussion, and they were the same professionals who had reviewed
and approved SCENESSE® for EPP in October 2019, thus the knowledge on SCENESSE® was current.

I like the sound of htis.
  Forum: By Share Code

seeva222
Posted on: May 1 2020, 05:31 AM


Group: Member
Posts: 1,679

An implant would still be preferable to oral IF you could get a local injection.
  Forum: By Share Code

seeva222
Posted on: May 1 2020, 02:56 AM


Group: Member
Posts: 1,679

I don't think the shorters care about MT-7117. They're looking at trends and liquidity.
  Forum: By Share Code

seeva222
Posted on: May 1 2020, 12:20 AM


Group: Member
Posts: 1,679

CLVLY popped $1 at the open
  Forum: By Share Code

seeva222
Posted on: Apr 30 2020, 02:26 AM


Group: Member
Posts: 1,679

https://www.facebook.com/1112753815441338/p...9530118729/?d=n
  Forum: By Share Code

seeva222
Posted on: Apr 29 2020, 11:29 AM


Group: Member
Posts: 1,679

HCQ has 90% chance of helping.

https://finance.yahoo.com/news/hydroxychlor...-155637974.html
  Forum: By Share Code

seeva222
Posted on: Apr 28 2020, 11:21 PM


Group: Member
Posts: 1,679

CUV Highlighting financial positioning.

https://www.linkedin.com/posts/clinuvel-pha...6099846145-TyMmLI

  Forum: By Share Code

seeva222
Posted on: Apr 28 2020, 10:27 PM


Group: Member
Posts: 1,679

So, is the new trademark aimed at covid-induced stroke? Or is this a coincidence? This whole thing seems out of left field.
  Forum: By Share Code

seeva222
Posted on: Apr 28 2020, 11:53 AM


Group: Member
Posts: 1,679

Roundup:

EPP: Started treating US patients with 3 centers open and expanding. Insurance reimbursement from 30 + insurers in place. Expanding into China with 5,000 patients. Oz on deck for July (150 days).
Vitiligo: Type C meeting with the FDA.
Variegate porphyria: EMA proof of concept.

  Forum: By Share Code

seeva222
Posted on: Apr 28 2020, 09:36 AM


Group: Member
Posts: 1,679

Can someone explain the significance of this? Are we talking about a drug that would impact vascular health?
  Forum: By Share Code

seeva222
Posted on: Apr 24 2020, 11:55 PM


Group: Member
Posts: 1,679

I agree,that's exactly the profile you're looking for.
  Forum: By Share Code

seeva222
Posted on: Apr 24 2020, 08:40 AM


Group: Member
Posts: 1,679

How many others are we targeting? Seems like a lot of greenfield between Europe and the US. Just give us one more indication (and I'm certain vitiligo will be one) and we're off to the races.
  Forum: By Share Code

seeva222
Posted on: Apr 23 2020, 06:56 PM


Group: Member
Posts: 1,679

This is ludicrous - there’s no reason in the world their local doctors can’t do it. Anyone medical professional and administer the implant. Hell, I’m not even sure you need medical training at all.
  Forum: By Share Code

seeva222
Posted on: Apr 23 2020, 10:14 AM


Group: Member
Posts: 1,679

A few were scheduled so unless something happened, they’ve got their implants.
  Forum: By Share Code

seeva222
Posted on: Apr 23 2020, 09:50 AM


Group: Member
Posts: 1,679

Wow. That was unexpected. US, China, Europe and Oz on deck. Vitiligo meeting happening in a week as well as cash receipts.
  Forum: By Share Code

seeva222
Posted on: Apr 23 2020, 09:20 AM


Group: Member
Posts: 1,679

Seeva222 wonders which character Ironbark222 was previously. Latest language sounds like Iggy
  Forum: By Share Code

seeva222
Posted on: Apr 22 2020, 03:50 AM


Group: Member
Posts: 1,679

What would the price be with no Covid? 30 USD at least.
  Forum: By Share Code

seeva222
Posted on: Apr 21 2020, 10:56 PM


Group: Member
Posts: 1,679

What skin conditions respond to afamelanotide?
Afamelanotide is registered to treat erythropoietic protoporphyria. It has been reported to be beneficial for patients with:

Solar urticaria
Vitiligo
Hailey-Hailey disease

Does afamelanotide work as a sunscreen?
The use of afamelanotide has been associated with a 50% decrease in epidermal cells from sunburn, as well as with a significant reduction in the formation of thymine dimer (part of the process by which UVB DNA damage ) However, marketers of afamelanotide do not recommend its use as a sunscreen or sunburn treatment.

The word is certainly gettin gout.
  Forum: By Share Code

seeva222
Posted on: Apr 21 2020, 01:47 AM


Group: Member
Posts: 1,679

Does anyone know what the hold times are on these (what their investment horizon is?) On the face of it, this looks like exactly the type of institutional portfolio you want supporting a stock.
  Forum: By Share Code

seeva222
Posted on: Apr 20 2020, 07:38 AM


Group: Member
Posts: 1,679

That is their model
  Forum: By Share Code

seeva222
Posted on: Apr 20 2020, 05:42 AM


Group: Member
Posts: 1,679

One of the problems with the euro rollout is that centers make no $$$ (at least according to one FB post. )
  Forum: By Share Code

seeva222
Posted on: Apr 20 2020, 05:02 AM


Group: Member
Posts: 1,679

That's the price quoted to me.
  Forum: By Share Code

seeva222
Posted on: Apr 18 2020, 11:31 PM


Group: Member
Posts: 1,679

If we get a handle on CV, it should be a good couple of months. The US EPP market alone is worth a $1-billion valuation.
  Forum: By Share Code

seeva222
Posted on: Apr 17 2020, 12:01 PM


Group: Member
Posts: 1,679

First implant preformed today in Miami. Type C Vitiligo meeting coming up. Cash receipts as well (could be disappointing).
  Forum: By Share Code

seeva222
Posted on: Apr 17 2020, 05:44 AM


Group: Member
Posts: 1,679

Dr. Grimes diagnosed my Vitiligo
  Forum: By Share Code

seeva222
Posted on: Apr 17 2020, 01:14 AM


Group: Member
Posts: 1,679

39k per implant off label, btw. IF it were available.
  Forum: By Share Code

seeva222
Posted on: Apr 16 2020, 10:49 PM


Group: Member
Posts: 1,679

We would certainly be over $40
  Forum: By Share Code

seeva222
Posted on: Apr 16 2020, 08:52 PM


Group: Member
Posts: 1,679

It's actually today!
  Forum: By Share Code

seeva222
Posted on: Apr 15 2020, 11:23 PM


Group: Member
Posts: 1,679

First US implant happening tomorrow.
  Forum: By Share Code

seeva222
Posted on: Apr 15 2020, 01:06 AM


Group: Member
Posts: 1,679

One day until US sales can commence. Recell announced this in January and took off in April.
  Forum: By Share Code

seeva222
Posted on: Apr 14 2020, 10:58 PM


Group: Member
Posts: 1,679

I love this. What were they at last month?
  Forum: By Share Code

seeva222
Posted on: Apr 13 2020, 10:27 AM


Group: Member
Posts: 1,679

3 Days until US treatments can commence. With the US looking to open up on May 1... we might get too far off track.
  Forum: By Share Code

seeva222
Posted on: Apr 10 2020, 04:41 AM


Group: Member
Posts: 1,679

So, who is Corbin? LH? Iggy?
  Forum: By Share Code

seeva222
Posted on: Apr 8 2020, 11:10 PM


Group: Member
Posts: 1,679

7 Days until US sales CAN commence. Have to believe the 3 centers have placed orders already.
  Forum: By Share Code

seeva222
Posted on: Apr 7 2020, 05:55 AM


Group: Member
Posts: 1,679

Find a stock that meets those criteria... curious how that has played out.
  Forum: By Share Code

seeva222
Posted on: Apr 7 2020, 01:37 AM


Group: Member
Posts: 1,679

ASX Strategies:

    Buy as a company gets into the ASX, sell after two weeks.
    If illiquid, wait for warrants to be issued and knocked out, then buy back.
    If FDA approved, sell a week after approval. Buy back a month before commercialization.
  Forum: By Share Code

seeva222
Posted on: Apr 6 2020, 10:22 AM


Group: Member
Posts: 1,679

10 days until this is available in the US.
  Forum: By Share Code

seeva222
Posted on: Apr 6 2020, 10:22 AM


Group: Member
Posts: 1,679

10 days until this is available
  Forum: By Share Code

seeva222
Posted on: Apr 6 2020, 03:36 AM


Group: Member
Posts: 1,679

What does “drop from formulary” mean?
  Forum: By Share Code

seeva222
Posted on: Apr 5 2020, 04:36 AM


Group: Member
Posts: 1,679

It shouldn't be just for cosmetics. It should be for skin protection... in Miami. What older person with skin damage isn't going to want this? It's a shame the FDA views this as a cosmetic treatment.
  Forum: By Share Code

seeva222
Posted on: Apr 4 2020, 11:07 PM


Group: Member
Posts: 1,679

I like this guy

https://www.drresnik.com/scenesse-implant-v...ami-florida.php
  Forum: By Share Code

seeva222
Posted on: Apr 4 2020, 12:02 AM


Group: Member
Posts: 1,679

Will cash flow be impacted in the short-term as these are preordered?
  Forum: By Share Code

seeva222
Posted on: Apr 1 2020, 05:59 AM


Group: Member
Posts: 1,679

About 80 per cent of the 4000 EPP sufferers in the US are covered by private insurance.
The next step is to seek Medicaid/Medicare reimbursement for the remainder.
Even though EPP is a tiny ‘orphan’ market, the company stands to generate more than $US300m ($500million) if it reaches just half the US patient market.
  Forum: By Share Code

seeva222
Posted on: Mar 31 2020, 11:15 AM


Group: Member
Posts: 1,679

We’re getting closer to US sales. If not for Coronahell we’d be at a new high in the next month.
  Forum: By Share Code

seeva222
Posted on: Mar 29 2020, 12:59 PM


Group: Member
Posts: 1,679

I do admire the approach to pricing (which is extremely hard to do and admirable) and to the medical coding which matters a great deal in the US. That said, it's time to shift strategy now to a market grab.
  Forum: By Share Code

seeva222
Posted on: Mar 27 2020, 12:50 PM


Group: Member
Posts: 1,679

Afamelanotide Works



Not to be lost in all of this
  Forum: By Share Code

seeva222
Posted on: Mar 27 2020, 12:36 PM


Group: Member
Posts: 1,679

Harris is really a douche. He’s flat out lying to people.
  Forum: By Share Code

seeva222
Posted on: Mar 27 2020, 09:57 AM


Group: Member
Posts: 1,679

He actually acted like he’d never heard of Scenesse on the vitiligo website.
  Forum: By Share Code

seeva222
Posted on: Mar 27 2020, 05:34 AM


Group: Member
Posts: 1,679

Harris is taking big pharma $$
  Forum: By Share Code

seeva222
Posted on: Mar 26 2020, 10:48 PM


Group: Member
Posts: 1,679

They should take the “clinic”’restrictions off. It’s a simple procedure with a safe drug.
  Forum: By Share Code

seeva222
Posted on: Mar 26 2020, 08:06 AM


Group: Member
Posts: 1,679

Anyone know the Whitehouse DR?
  Forum: By Share Code

seeva222
Posted on: Mar 24 2020, 09:43 AM


Group: Member
Posts: 1,679

I'll bet we'd be knocking on 40 without the world p;ossibly ending.
  Forum: By Share Code

seeva222
Posted on: Mar 24 2020, 05:56 AM


Group: Member
Posts: 1,679

They've already said they're not going to ban shorts. Too bad, coupled with US distribution and easing up on coronahell, it could really cause a ruse.
  Forum: By Share Code

seeva222
Posted on: Mar 24 2020, 01:07 AM


Group: Member
Posts: 1,679

Today would(still could?) have been the start of a year long run-up. The shorts would have disappeared. I still can't believe management is focused on topicals and M&A while targeting a lackidasical roll-out... the first rule of business is to execute your core business..
  Forum: By Share Code

seeva222
Posted on: Mar 23 2020, 11:31 AM


Group: Member
Posts: 1,679

First patient is April 15

https://yourir.info/resources/fee77b1d1a878...SA_in_April.pdf
  Forum: By Share Code

seeva222
Posted on: Mar 23 2020, 05:00 AM


Group: Member
Posts: 1,679

Can you take a breather and aggregate your thoughts? Appreciate it, but every day it's big long Wally posts. I don't read them because they're too frequent and somewhat redundant. Said with love.
  Forum: By Share Code

seeva222
Posted on: Mar 19 2020, 11:44 AM


Group: Member
Posts: 1,679

A newsletter with news
  Forum: By Share Code

seeva222
Posted on: Mar 18 2020, 12:39 AM


Group: Member
Posts: 1,679

Hey Walnut, offer up Scenesse's help if needed!
  Forum: By Share Code

seeva222
Posted on: Mar 17 2020, 01:54 PM


Group: Member
Posts: 1,679

“Short traders in the market are reportedly furious with the decisions by UniSuper, which only gives them days to return borrowed stock.”
  Forum: By Share Code

seeva222
Posted on: Mar 16 2020, 01:17 PM


Group: Member
Posts: 1,679

https://www.afr.com/politics/federal/fryden...20200313-p549p9
  Forum: By Share Code

seeva222
Posted on: Mar 16 2020, 10:05 AM


Group: Member
Posts: 1,679

Uh, yeah. Sniffing frauds out is always useful
  Forum: By Share Code

seeva222
Posted on: Mar 15 2020, 11:38 AM


Group: Member
Posts: 1,679

Perhaps I'm mistaken, I thought someone posted the critieria before.
  Forum: By Share Code

seeva222
Posted on: Mar 15 2020, 05:30 AM


Group: Member
Posts: 1,679

It will certainly be delayed. The critieria for participants was pretty wide open too. It wasn't just EPP patients, I believe almost anyone could take part. Odd.
  Forum: By Share Code

seeva222
Posted on: Mar 14 2020, 01:08 PM


Group: Member
Posts: 1,679

delete
  Forum: By Share Code

seeva222
Posted on: Mar 14 2020, 01:08 PM


Group: Member
Posts: 1,679

https://papers.ssrn.com/sol3/Delivery.cfm/S...617&mirid=1
  Forum: By Share Code

seeva222
Posted on: Mar 14 2020, 04:45 AM


Group: Member
Posts: 1,679

I would expect shorts to want to close out if they can't count on pushing th emarket down.
  Forum: By Share Code

seeva222
Posted on: Mar 14 2020, 04:32 AM


Group: Member
Posts: 1,679

If they ban shorts, I'm going to start buying.
  Forum: By Share Code

seeva222
Posted on: Mar 14 2020, 03:10 AM


Group: Member
Posts: 1,679

Italy and Spain ban shorting

Short-selling restrictions were also put in place for some Asian markets, with South Korea’s Financial Services Commission going the furthest by banning short-selling of shares listed on Kospi, Kosdaq and Konex for six months. In Thailand, short sales were not banned, but rules are being adjusted for current market conditions, according to the President of the country’s stock exchange.

https://www.bloomberg.com/news/articles/202...n-short-selling
  Forum: By Share Code

seeva222
Posted on: Mar 13 2020, 12:37 PM


Group: Member
Posts: 1,679

That will change things
  Forum: By Share Code

seeva222
Posted on: Mar 13 2020, 09:17 AM


Group: Member
Posts: 1,679

I agree. It's a liability problem masked as corporate caring. At some point the liability shifts from corporations to the individual and you get on the plane or you don't have a job.
  Forum: By Share Code

seeva222
Posted on: Mar 13 2020, 04:39 AM


Group: Member
Posts: 1,679

It's a broad-based panic sell, small caps get murdered first. The good news here is a strong balance sheet and increasing sales.
  Forum: By Share Code

seeva222
Posted on: Mar 12 2020, 10:46 PM


Group: Member
Posts: 1,679

  Forum: By Share Code

seeva222
Posted on: Mar 12 2020, 02:56 PM


Group: Member
Posts: 1,679

Technology for at least four diseases, consumer goods, and different business lines. Interesting
  Forum: By Share Code

seeva222
Posted on: Mar 12 2020, 03:52 AM


Group: Member
Posts: 1,679

Unless corona virus bankrupts healthcare systems, this shitstorm means nothing to the long-term value of the company and if we're truly going to buy other companies with our cash flow, the price of acquisition just went down considerably. The problem from a shareholder perspective is that small and mid cap valuations shrink much faster than large cap in a downturn.
  Forum: By Share Code

seeva222
Posted on: Mar 11 2020, 12:45 AM


Group: Member
Posts: 1,679

CORRECTION: The Public Meeting on Patient-Focused Drug Development for Vitiligo, not the Type C meeting has been postponed. My apologies.

https://www.fda.gov/drugs/news-events-human...302020-03302020

  Forum: By Share Code

seeva222
Posted on: Mar 10 2020, 01:01 PM


Group: Member
Posts: 1,679

And it turns out Dr. Lim's Detroit Henry Ford System takes Aetna, not sure about BCBS of Michigan, but I would assume that's not a coincidence. UCLA takes Aetna as well.
  Forum: By Share Code

seeva222
Posted on: Mar 10 2020, 12:43 PM


Group: Member
Posts: 1,679

BTW, 6 doses a year for Centene and Aetna. At a 1/200,000 ratio, that's about $17-million in annually recurring revenue.
  Forum: By Share Code

seeva222
Posted on: Mar 10 2020, 12:11 PM


Group: Member
Posts: 1,679

Another 23 million insured to go with Aetna's 22 million,
  Forum: By Share Code

seeva222
Posted on: Mar 10 2020, 07:47 AM


Group: Member
Posts: 1,679

Email. Sounds corona related
  Forum: By Share Code

seeva222
Posted on: Mar 10 2020, 07:47 AM


Group: Member
Posts: 1,679

Email. Sounds corona related
  Forum: By Share Code

seeva222
Posted on: Mar 10 2020, 07:47 AM


Group: Member
Posts: 1,679

Email. Sounds corona related
  Forum: By Share Code

seeva222
Posted on: Mar 10 2020, 06:51 AM


Group: Member
Posts: 1,679

Type C meeting delayed due to “circumstances”
  Forum: By Share Code

seeva222
Posted on: Mar 9 2020, 11:41 PM


Group: Member
Posts: 1,679

I don't think they're recruiting EPP patients are they?
  Forum: By Share Code

seeva222
Posted on: Mar 9 2020, 11:24 AM


Group: Member
Posts: 1,679

Well, I’ll give Walnut credit for one thing. Strong Balance sheets are key in downturns.
  Forum: By Share Code

seeva222
Posted on: Mar 7 2020, 12:23 AM


Group: Member
Posts: 1,679

Read the annual. It’s a “self-administered” model. They seem to think they can guide this to the APF and go work on other things.
  Forum: By Share Code

seeva222
Posted on: Mar 6 2020, 11:00 PM


Group: Member
Posts: 1,679

Good chance? 50% is a pipe dream
  Forum: By Share Code

seeva222
Posted on: Mar 6 2020, 11:00 PM


Group: Member
Posts: 1,679

Good chance? 50% is a pip dream
  Forum: By Share Code

seeva222
Posted on: Mar 6 2020, 11:46 AM


Group: Member
Posts: 1,679

their entire “let everyone else do all the work” philosophy is moronic and short sighted. They’re doing it so they can concentrate on cosmeceuticals and M&A. Morons
  Forum: By Share Code

seeva222
Posted on: Mar 6 2020, 04:09 AM


Group: Member
Posts: 1,679

It's an absolute long-term bargain, but market timing is an issue. Imagine if we didn't get FDA approval?
  Forum: By Share Code

seeva222
Posted on: Mar 5 2020, 05:12 AM


Group: Member
Posts: 1,679

They didn't spend months patting themselves on the back for approval? The actually went out to monetize? Crazy
  Forum: By Share Code

seeva222
Posted on: Mar 4 2020, 11:27 PM


Group: Member
Posts: 1,679

Clinuvel should see where they’re launching and open up a Centre there. Why is it 5-7 years?
  Forum: By Share Code

seeva222
Posted on: Mar 4 2020, 11:27 PM


Group: Member
Posts: 1,679

Clinuvel should see where they’re launching and open up a Centre there. Why is it 5-7 years?
  Forum: By Share Code

seeva222
Posted on: Mar 4 2020, 09:38 AM


Group: Member
Posts: 1,679

CSL now #1
https://www.theaustralian.com.au/subscribe/...08aa-1583278672
  Forum: By Share Code

seeva222
Posted on: Mar 4 2020, 07:15 AM


Group: Member
Posts: 1,679

https://www.uclahealth.org/simon-beaven
https://www.aasld.org/programs-initiatives/...-md-faasld-agaf
https://www.henryford.com/physician-directory/l/lim-henry
  Forum: By Share Code

seeva222
Posted on: Mar 4 2020, 04:48 AM


Group: Member
Posts: 1,679

Guesses:
Dr. Cynthia Levy at Miami
Dr. Heny LIm at Henry Ford Hospital, Detroit, MI
LA?

BTW: https://www.drresnik.com/scenesse-implant-v...ami-florida.php
  Forum: By Share Code

seeva222
Posted on: Mar 4 2020, 04:26 AM


Group: Member
Posts: 1,679

Miami, Detroit and LA?

https://scenesse.com/public/epp-centers/
  Forum: By Share Code

seeva222
Posted on: Mar 3 2020, 08:03 PM


Group: Member
Posts: 1,679

Now someone needs to find UHC and Cigna.
  Forum: By Share Code

seeva222
Posted on: Mar 3 2020, 01:11 PM


Group: Member
Posts: 1,679

Wolgren. WTF is wrong with you? EPP patients can’t find info easily. Me while you’re fishing for cosmeceutical grants that you would get in one week of an EPP rollout.

Malfeasance.

  Forum: By Share Code

seeva222
Posted on: Mar 3 2020, 10:32 AM


Group: Member
Posts: 1,679

Avita involves abrating the skin and spraying new skin on. That’s pretty intense. . I see these as complementary
  Forum: By Share Code

seeva222
Posted on: Mar 2 2020, 08:42 PM


Group: Member
Posts: 1,679

At some point, even if it stays down, the market will start differentiationing between companies that will be impacted by the virus (cruise lines are fucked) and those that are less so,

Clinical has to be among the least impacted categories.
  Forum: By Share Code

seeva222
Posted on: Mar 2 2020, 02:07 PM


Group: Member
Posts: 1,679

Took out the last warrants

  Forum: By Share Code

seeva222
Posted on: Mar 2 2020, 12:50 PM


Group: Member
Posts: 1,679

CUV unaffected by corona
https://www.asx.com.au/asxpdf/20200302/pdf/...nrdc5tnbtyf.pdf
  Forum: By Share Code

seeva222
Posted on: Mar 1 2020, 10:04 AM


Group: Member
Posts: 1,679

They are no longer pursing nasdaq
  Forum: By Share Code

seeva222
Posted on: Mar 1 2020, 09:08 AM


Group: Member
Posts: 1,679

So why did he emphasize listing on the NASDAQ Only to retreat from that perspective? Meanwhile the shorts in Australia are hammering the stock.
  Forum: By Share Code

seeva222
Posted on: Feb 29 2020, 08:52 AM


Group: Member
Posts: 1,679

Would a Nasdaq listing quiet the short problem?
  Forum: By Share Code

seeva222
Posted on: Feb 28 2020, 01:30 PM


Group: Member
Posts: 1,679

The virus will have no effect on Clinuvel and balance sheets win in downturns. So, bargain prices for sure over the long term.

Short term? Who knows.
  Forum: By Share Code

seeva222
Posted on: Feb 27 2020, 01:42 PM


Group: Member
Posts: 1,679

They’ve also got the Baltic Sea covered.

These jokers just made inorganic growth one of their four pillars.

They can’t even get a map right... company integration absolutely blows as does the debt that comes with such an acquisition. Bad integration, imagines synergies and debt bring down most acquisitions.
  Forum: By Share Code

seeva222
Posted on: Feb 26 2020, 07:21 PM


Group: Member
Posts: 1,679

I want them to invest, but Where are the investments going? To the US roll-out? I’m all for a cosmeceutical play, but let’s scoop up the markets we’ve already made first.
  Forum: By Share Code

seeva222
Posted on: Feb 26 2020, 10:37 AM


Group: Member
Posts: 1,679

There are few better opportunity plays right now other than your mattress
  Forum: By Share Code

seeva222
Posted on: Feb 26 2020, 09:34 AM


Group: Member
Posts: 1,679

It’s actually one of the perfect stocks to buy as it’s a guaranteed annuity for an orphan indications so highly unlikely to get cut. Then you add in growth potential… What’s concerning is management is already thinking about in organic growth before they made any real money.


Get the rollout done PW
  Forum: By Share Code

seeva222
Posted on: Feb 25 2020, 01:23 AM


Group: Member
Posts: 1,679

Cramer sees biotechs as refuge

https://www.cnbc.com/2020/02/24/jim-cramer-...ven-plunge.html
  Forum: By Share Code

seeva222
Posted on: Feb 23 2020, 09:45 AM


Group: Member
Posts: 1,679

Sun tan threatens the coral reef

https://www.instagram.com/tv/B8367tYB0ii/?i...id=zsar04mdx61o
  Forum: By Share Code

seeva222
Posted on: Feb 22 2020, 07:06 AM


Group: Member
Posts: 1,679

Thanks for the translation! Very helpful
  Forum: By Share Code

seeva222
Posted on: Feb 20 2020, 07:34 AM


Group: Member
Posts: 1,679

And how many employees are on this mission critical task????

Imagine trying to get $100 million rollout underway while relying on a nonprofit to do all of your legwork?

How dumb would that make you?
  Forum: By Share Code

seeva222
Posted on: Feb 20 2020, 01:44 AM


Group: Member
Posts: 1,679

If you had cashed and bought Avita preapproval, you would have been down at the same point in time. Avita Went from 1.7 to 1.1. I went for that ride.

It didn’t start rising until March the following year.
  Forum: By Share Code

seeva222
Posted on: Feb 15 2020, 04:30 AM


Group: Member
Posts: 1,679

You’re on fire. Thanks
  Forum: By Share Code

seeva222
Posted on: Feb 14 2020, 03:26 AM


Group: Member
Posts: 1,679

How big is the market in Oz? Is off-label easier there? Seems to me this is a S/C drug waiting to happen D/U
  Forum: By Share Code

seeva222
Posted on: Feb 14 2020, 02:02 AM


Group: Member
Posts: 1,679

APF Facebook thread below.
  Forum: By Share Code

seeva222
Posted on: Feb 14 2020, 12:11 AM


Group: Member
Posts: 1,679

“At the earliest “

We all know how they work with timelines
  Forum: By Share Code

seeva222
Posted on: Feb 13 2020, 11:52 PM


Group: Member
Posts: 1,679

They told EPP patients it would be April at the earliest
  Forum: By Share Code

seeva222
Posted on: Feb 12 2020, 01:13 AM


Group: Member
Posts: 1,679

Here's the thing, despite the hamfisted manner in which this is rolling out, in spite of themselves, they're very quickly going to get to $100-million in revenue and then $200 and that's an annuity. Meanwhile they'll be chasing other indications with huge potential (vitiligo, DNA repair) and playing out the cosmesceutical path. I just don't understand the slow roll in the US, they should have had lists of patients ready to go.
  Forum: By Share Code

seeva222
Posted on: Feb 12 2020, 01:09 AM


Group: Member
Posts: 1,679

Exec Summary if someone wants to summarize the summary.

Executive summary
NEW DRUG APPROVALS AND LAUNCHES
A record number of new active substances (NAS) were
approved and launched in the United States in 2018,
bringing new treatment options to patients. Among
these 59 NASs, 27% are new therapies to treat cancer
and its symptoms and 20% are for the treatment of
infectious diseases. Almost half of these therapies
carried an orphan drug designation and over a third
of NAS launches were identified by the FDA as first-inclass, having mechanisms of action different from those
of existing therapies.

Translating a scientific breakthrough to the development
of a therapeutic medicine remains a slow process, with
the 2018 cohort of NASs taking a median of 13.6 years
from the time of first patent filing to launch. Still, the 2018
NASs launched approximately two years faster than
those in the prior two years. Among the 2018 new drug
launches, 12 drugs were launched more than 20 years
after their first patent filing, reflecting in some cases
drugs with older mechanisms of action being repurposed
and drugs that had previously launched globally but
not in the United States. Over two-thirds of new drugs
in 2018 came through the regulatory process under one
of several tracks intended to accelerate development
and review, but over the past three years only those with
accelerated approval and breakthrough status have seen
significantly shorter times from patent filing to launch.
Of the NASs launched in 2018, 46% were also approved
based on data from trials with fewer than 500 subjects
in total, as drugs types are increasingly specialty, niche
and orphan drugs, which typically enroll fewer subjects.
In addition, the amount of time a drug has been tested
in a patient population at time of approval — patientyears at approval — is declining.


The companies bringing these drugs to the market are
also changing. Emerging biopharma (EBP) companies
patented almost two-thirds of these new drugs and
registered 47% of them, while large pharma companies
patented one-quarter of the total. The critical role of
emerging biopharma companies in sourcing innovative
medicines has expanded significantly since 2010,
when they registered 33% of the drugs launched
that year. Although the importance of large pharma
in originating molecules is decreasing, they remain
important partners for EBP companies even as EBP are
increasingly able to commercialize alone. Large pharma
companies registered nearly half of the new drugs
in 2018, approximately half of which originated with
emerging biopharma companies.

CLINICAL DEVELOPMENT PIPELINE
As levels of life science investment continue to grow, the
pipeline of therapies still under development similarly
has been expanding. The number of molecules in latestage development now totals 2,891, increasing 11% in
2018 and 39% over the past five years. Oncology drugs
increased in number by 63% over the past five years,
contributing over 40% of the total pipeline increase,
while the number of vaccines under development has
declined over this period by 4%. Pain and dermatology
drugs also increased over 50% since 2013 but represent
just under 6% of the total pipeline each. Therapy areas
that have seen the biggest increase in activity over
the past year are those focused on oncology, ALS and
other degenerative musculoskeletal conditions, rare
diseases related to the GI tract, and non-narcotic pain
treatments.

Next-Generation Biotherapeutics (NGB) including
cell, gene and nucleotide therapies — though they still
represent less than 10% of the total late-stage R&D
pipeline – have more than doubled in number over the
past three years, as these new approaches to treating
and curing diseases command growing attention and
investment. Three NGBs were launched in 2018, and
though fewer than 20 are now available to patients,
they reflect recent and growing advances and activity in
oncology, neurology and rare diseases.

EBP companies, active in the fastest growing areas of
oncology and orphan drugs, also accounted for 72%
of the 2018 late-stage pipeline activity, up from 61% a
decade ago. Large pharma companies have seen their
share of the pipeline drop from 31% to 20% over the
same period.

Investment in future medical innovation continued
to grow in 2018 reflecting confidence in scientific
innovation to tackle unmet health needs. Venture
capital firms invested over $23 billion in 2018, with a
record number of deals recorded, and the 15 largest
pharmaceutical companies recorded more than
$100 billion in R&D expenditure for the first time, up
32% over the past five years.

CLINICAL TRIAL ACTIVITY
The total number of clinical trials that started in 2018
similarly indicate robust R&D growth of 9% over the
prior year and 35% over the past five years. Most of this
increase is due to the number of Phase II trials, which
increased 26% in 2018 and 61% over the level five years
ago, driven by oncology and neurology trials. Clinical
trials across phases in GI/NASH and oncology have
increased significantly, up 42% and 27%, respectively in
2018, while trial activity in the other major therapy areas,
such as endocrinology and respiratory, has declined.

The composite progression time from the initiation
of Phase I clinical development for a drug until a
registration decision is reached was 12.5 years in
2018, up six months from 2017, and resuming the
gradual lengthening of progression time for all drugs
in development. The composite success rate of
clinical development from Phase I trials to regulatory
submission — based on the percent of drugs successfully
progressing to each next stage of development — fell to
11.4% in 2018, down from 14.4% in 2017, and was below
the average of 14% in the prior ten years. All stages of
clinical development saw declines in success rates in
2018, with Phase I and Phase III trial success both falling
by 7−8%. Success rates by development stage have all
generally been consistent over the past decade, with
2015 an exceptional year, when the composite success
rate exceeded 22%. While therapy classes and drug
types under development have changed during the
past decade, oncology has had slightly lower composite
success rates (12%) than non-oncology (14.1%).
To examine the productivity of the clinical development
process, a Clinical Development Productivity Index was
developed measuring trial success in relation to the
effort invested in trials. Applying this new metric across
trials in nine of the largest therapy areas showed that
productivity has declined overall from 2013 to 2018
falling 27% from 2013 to 2018, heavily influenced by
a decrease in productivity in Phase I of 55% over that
period, and declines in Phase III since 2016. Phase II and
Phase III trial productivity remained relatively stable
since 2010. Declining productivity in Phase I was driven
by declines in success rates of 7% and increases in trial
complexity (which includes numbers of trial participants,
eligibility criteria, research sites countries, and endpoints)
of 6%. In 2018, complexity rose due to increases in all
complexity elements excepting the number of trial sites
and countries. For instance, the number of patients
expected to participate in clinical trials across the nine
key therapy areas increased 10% over 2017 with growth
influenced by an increase of the number of patients in
Phase III oncology and neurology trials.
The notable successes and failures of 2018 have also
shifted our understanding of human science, disease
and treatment. Since 2008 in Alzheimer’s disease,
only one product received regulatory approval, while
86 other development projects were discontinued,
including four in 2018. In NASH, nine new drugs were
added to the late-phase pipeline as drugs with several
mechanisms continue to show promise in research.
There were also some notable failures in cancer,
including the IDO mechanism and some with PD-1s,
where other drugs had succeeded in the same tumors.
However, these were offset by the large numbers of
approvals and the continued flow of breakthroughs in
other disease areas.

DRIVERS OF CHANGE IN CLINICAL DEVELOPMENT
Eight key trends in technology, science and data use
are currently influencing clinical development. Their
impact on trial design and complexity, duration and
success was explored through the IQVIA Clinical
Development Trends Impact Assessment completed
by IQVIA therapy area experts. All trends were
considered to have a high likelihood of impact, with
the probability of impact ranging between 74–85%.
The timing of trends is similar with all trends reaching
their peak impact within 2.5–4.0 years.
Digital health and mobile technologies will enable
the capture of drug efficacy and safety data remotely
within the bounds of clinical trials, and are therefore
expected to improve patient safety, enable virtual
trial formats and ease site work burden. They will also
make it easier to capture patient-reported outcomes
(PRO), which are expected to shed new light on patient
experience, as well as drug efficacy and safety outside
the clinical setting, and lead to accelerated trial times
as endpoints shift.
The emergence of new data sources and analytic tools
are also changing clinical development. Curated realworld data (RWD) sources will be used to optimize trial
design, speed trials by aiding selection of investigators
and sites, and enable new trial designs – e.g. by acting
as virtual/synthetic control arms and supporting
pragmatic, adaptive and real-world evidence (RWE)
registry trial designs. On top of RWD and other big
data in healthcare, predictive analytics and artificial
intelligence (AI) are expected to identify new clinical
hypotheses to test, minimize trial design risks and
speed enrollment by identifying protocol-ready patients
or by predicting which patients have disease and may
be eligible for recruitment.

Shifts in the regulatory landscape were deemed the
most likely to have an effect on clinical development
with an 85% likelihood of impact across therapy
areas. Expected to improve the likelihood of success,
regulatory changes are expected to further the
adoption of precision medicine approaches, enable the
use of novel trial designs and endpoints and generally
provide means for accelerated drug approvals.
Changes in scientific advances – shifts in drugs types
being tested and biomarker test availability – are
next most likely to impact clinical development and
will affect greater than five therapy areas within just
2.5 years. Shifts in types of drugs being tested to
disease modifying drugs, targeted therapies and NextGeneration Biotherapeutics will improve efficacy and
success rates and accelerate development timelines,
but will require longer-term patient follow up. The
increased availability and ease of biomarker testing will
allow for novel trial designs like basket trials, and help
to narrow patient populations to those more likely to
see effect, resulting in improvements in efficacy, safety
and success.
Finally, the availability of pools of pre-screened patients
and direct-to-patient recruitment are expected to
facilitate trial recruitment, helping sites to hit accrual
targets, decreasing trial duration and leading to
accelerated market availability.

Many of the therapy areas with the most complex trials
will see impacts of these trends within three years.
At a therapy area level, GI/NASH, neurology and
cardiovascular trials are the most likely to see rapid
changes over the next several years with changes
resulting from nearly all trends.

MODELING FUTURE TRIAL PRODUCTIVITY
The Clinical Development Trends Impact Assessment
was also used to model the future expected impact
of each key market trend on clinical development
productivity across trial phases and the nine key
therapeutic areas. Results show that each trend will have
a differential impact on trial productivity, success and
effort across therapy areas in the next five years. For
example, biomarkers will have the greatest impact on
clinical productivity yielding a 34% average increase
across therapy areas and trial phases and the greatest
increases in success rates (+27%). Similarly, pools of
pre-screened patients will yield a high increase in
productivity of 29% on average by driving the largest
average declines in effort, at -11%.

Trends impacting productivity varied by therapy
area. In oncology, pools of pre-screened patients
will accelerate trial recruitment and biomarkers
will improve success rates, leading to productivity
improvements as high as 104% and 71%, respectively.
Biomarkers will also yield consistently high
improvements in productivity of over 45% across four
other therapy areas: GI/NASH, rare disease, neurology
and cardiovascular. In addition, oncology and
neurology trials will see approximately 30% or greater
improvements in productivity over the next five years
— the largest increases in productivity across therapy
areas — while respiratory will see the largest decrease in
productivity.

Along with biomarkers, neurology trials will see the most
significant impact from regulatory changes and digital
health. Respiratory trials, however, will only see positive
productivity effects from RWD and predictive analytics
– both derived from the growth in the use of big data
and its analysis. While trends vary in their impact
on productivity across phases, the most significant
productivity changes will occur in Phase II trials.
  Forum: By Share Code

seeva222
Posted on: Feb 11 2020, 06:58 AM


Group: Member
Posts: 1,679

Oh, I’m sure he’s getting his iggy on right now. As down as I am on management and their delayed distribution once US distribution starts happening then things will change.

In the meantime I challenge each and everyone of you to tell Donald Trump that he doesn’t have to have a spray on tan. He needs to make this available to the masses.

Trumps vanity could help us! https://action.donaldjtrump.com/president-t...dAaAjJsEALw_wcB
  Forum: By Share Code

9 Pages (Click to Jump) V   1 2 3 4 > » 

Cant find what you are looking for? Show all active topics from the last 3 months


New Posts  New Replies
No New Posts  No New Replies
Hot topic  Hot Topic (New)
No new  Hot Topic (No New)



TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING